Description
Bacteriostatic water (bac water) is sold separately.
Potential Benefits — Research Is Ongoing
Potential benefits below relate to cagrilintide research in controlled human trials; this B&A presentation has not undergone those trials.
- Fullness and satiety: May strengthen the feeling of having eaten enough.
- Appetite management: May help reduce hunger through amylin-related appetite signalling.
- Food-intake reduction: May support eating less as satiety increases.
- Weight reduction: May support meaningful weight loss in adults with overweight or obesity.
Research sources: Cagrilintide phase-2 trial; REDEFINE-1 trial.
Research Overview
Cagrilintide is investigated as a long-acting amylin analogue in controlled weight-management research. Published studies concern their specified trial formulations, not this B&A presentation.
Mechanism / Pathway
Cagrilintide is a long-acting amylin analogue. Research examines amylin-related appetite and satiety signalling. Biological activity does not validate the compatibility or stability of a commercial research presentation.
Published Research
Scientific Profile
- Identity: Cagrilintide
- Compound class: Long-acting amylin analogue
- Labelled amount: 5 mg total per vial; not a dose
- Evidence limitation: The linked trial is not a test of this B&A formulation
Research Areas
- Amylin-related satiety pathways
- Body-weight outcomes in controlled trials
- Gastrointestinal tolerability and formulation-specific safety
Cagrilintide 5 mg Vial
Cagrilintide, supplied as lyophilised powder in a B&A Premium vial with a holographic product label.
About this vial presentation
Cagrilintide 5 mg Vial is supplied as one vial in the B&A Premium range. The labelled amount of 5 mg refers to the total contents of the vial, rather than a dose or liquid volume. Use the actual batch label to confirm identity, total dry content, storage and expiry information. This vial is supplied as lyophilised powder, not as a liquid or ready-made solution.
Browse the vial collection to compare product names, quantities and formats. Bacteriostatic water is sold separately; this does not establish that it is compatible with this formulation. For documentation relating to Cagrilintide 5 mg Vial, contact B&A Premium with the batch reference.
Product details
- Contents: Cagrilintide
- Labelled amount per vial: 5 mg
- Presentation: lyophilised powder in a vial
- Pack: 1 vial
Storage
Keep refrigerated at 2–8°C and protected from light. Follow the batch label for expiry and handling instructions.
Important research information
For research use only. The labelled amount is the total content per vial, not a dose. Product artwork is illustrative; consult the supplied label for batch-specific details.
Looking for another presentation? View the Cagrilintide 5 mg prefilled pen. Compare each listing’s format and labelled contents; vial powder and prefilled pens are separate presentations.
Warnings, Contraindications & Safety Information
Research use only. This is an evidence-limited safety summary, not a package insert, complete prescribing information or permission for self-administration. References to licensed medicines describe those specific products; they do not establish B&A product approval, equivalence or safety.
Contraindications & Who Should Avoid Exposure
A clinically validated contraindication list for this exact research presentation has not been established. That absence is not evidence of safety. Do not expose a person with a known allergy to a labelled ingredient or excipient.
Warnings & Precautions
This research presentation has not been established as safe for human administration. Do not use during pregnancy or breastfeeding, or in children. A serious medical condition, including cancer or significant liver or kidney disease, requires professional assessment; this page cannot establish suitability. Cagrilintide studies have reported gastrointestinal symptoms and administration-site reactions. Trial findings do not establish the safety of this formulation.
Possible Adverse Reactions
Cagrilintide trial participants reported nausea, constipation, diarrhoea and administration-site reactions. A complete risk profile for this research vial and its excipients is not established.
Drug & Supplement Interactions
Drug and supplement interactions have not been adequately characterised for this presentation. Do not assume that combining it with prescription medicines, hormones or other research compounds is safe. Give a clinician the full ingredient list if exposure has occurred.
When to Seek Urgent Help
Seek emergency care for difficulty breathing, swelling of the face or throat, collapse, severe persistent abdominal pain, or repeated vomiting with inability to keep fluids down. Stop further exposure and show the clinician the product label and ingredient list.
Handling & Storage Cautions
Follow the actual product label and batch-specific expiry information. Do not use damaged, contaminated or unexpectedly changed material. Powder appearance, refrigeration or addition of bacteriostatic water does not prove sterility, compatibility or a safe shelf life. Do not share needles, pens or opened material between people.
Safety references: Cagrilintide phase 2 trial. Information reviewed 20 October 2026.
Reviews
There are no reviews yet.